Endocrine Abstracts

Objective: To evaluate cancer risk among people with type 2 diabetes mellitus (T2DM) in Lithuania.

Methods: A retrospective cohort design was used. The cohort was established by identifying all patients with the first diagnosis of T2DM in the National Health Insurance Fund database during 2000–2012. Cancer cases were identified by record linkage with the Lithuanian Cancer Registry. Standardized incidence ratios (SIRs) were calculated.

Results: 127 290 people were included and 5959 cases of cancer in men and 6661 cancer cases in women with T2DM were observed. Statistically significant increase in risk for all cancer sites was observed in women, SIR 1.16 (95% CI 1.14–1.19), but not in men, SIR 1.00 (95% CI 0.98–1.03). Among males, significant increase of liver (SIR 2.11, 95% CI 1.79–2.49]), pancreas (SIR 1.77, 95% CI 1.57–1.99), kidney (SIR 1.46 95% CI 1.31–1.62), thyroid (SIR 1.83, 95% CI 1.32–2.54), colorectal (SIR 1.23, 95% CI 1.14–1.31]), skin melanoma (SIR 1.40, 95% CI 1.11–1.76) and non–melanoma skin (SIR 1.14, 95% CI 1.05–1.23) cancer was observed. For females with T2DM, significant increase in risk of cancer of the liver (SIR 1.45, 95% CI 1.17–1.79), pancreas (SIR 1.74, 95% CI 1.56–1.93), kidney (SIR=1.43, 95% CI 1.28–1.60), thyroid (SIR=1.40, 95% CI 1.22–1.62), breast (SIR=1.24, 95% CI 1.17–1.31) and corpus uteri (SIR 2.07, 95% CI 1.93–2.21) was observed.

Conclusion: People with T2DM in Lithuania have an increased risk of site-specific cancer.